Literature DB >> 27585210

Venous sinus stenting in idiopathic intracranial hypertension: a safer surgical approach?

Sona Chaudhry1, Tara K Bryant, Crandall E Peeler.   

Abstract

PURPOSE OF REVIEW: The purpose is to summarize treatment strategies in idiopathic intracranial hypertension (IIH), a potentially sight-threatening disease, with a focus on the most current outcome data for venous sinus stenting. RECENT
FINDINGS: Historically, the primary treatment options for medically refractory IIH consisted of either optic nerve sheath fenestration or cerebrospinal fluid diversion procedures. The visual outcomes of these procedures are favorable, though they tend to be associated with a high rate of complication and failure. Recent trials suggest that venous sinus stenting offers both comparable rates of efficacy - with improved papilledema in 97% of patients, resolved headache in 83%, and improved visual acuity in 78% - and improved safety and reliability relative to older surgical techniques.
SUMMARY: Patients whose sight is threatened by medically refractory IIH must often consider invasive procedures to control their disease. Venous sinus stenting may offer equal efficacy and lower failure and complication rates than traditional surgical approaches such as optic nerve sheath fenestration and cerebrospinal fluid diversion.

Entities:  

Mesh:

Year:  2016        PMID: 27585210     DOI: 10.1097/ICU.0000000000000315

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  2 in total

Review 1.  [Indications and technique for transconjunctival optic nerve sheath fenestration : Video article].

Authors:  W A Lagrèze; N Gross; J Biermann; L Joachimsen
Journal:  Ophthalmologe       Date:  2017-10       Impact factor: 1.059

2.  Regarding "Safely Traversing Venous Sinus Stenosis: The 'Cobra' Technique".

Authors:  John C Dalfino; Pouya Entezami; Nicholas C Field; Andrew K Rock
Journal:  Interv Neuroradiol       Date:  2021-10-11       Impact factor: 1.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.